Prognostic significance of pan-immune-inflammatory value in adverse cardiovascular and cerebrovascular events post-percutaneous coronary intervention in diabetic patients with coronary heart disease
Frontiers in Cardiovascular Medicine · 07.07.2026 · 13
DOI: 10.3389/fcvm.2026.1750706 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 07.07.2026. Verfasst von Qinghong Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Luzhou People's Hospital, Luzhou, Sichuan, China. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The pan-immune-inflammation value (PIV) is a novel biomarker reflecting systemic inflammation. Its role in predicting adverse cardiovascular and cerebrovascular events in diabetic patients after percutaneous coronary intervention (PCI) is unclear.
Objectives
This study evaluated PIV's prognostic value for major adverse cardiovascular and cerebrovascular events (MACCE) post-PCI in diabetics with coronary heart disease (CHD), and compared it to other inflammation-based markers like systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR).
Methods
Retrospective analysis of diabetic CHD patients undergoing PCI. PIV was calculated as (neutrophil × platelet × monocyte)/lymphocyte counts from pre-procedural blood. Optimal cutoff determined via ROC curve. Patients stratified into high/low PIV groups. Follow-up for MACCE (e.g., MI, stroke, revascularization). Kaplan–Meier (KM) survival, Cox regression, and ROC comparisons assessed outcomes.
Results
Over 24-month median follow-up, 52 MACCE occurred (24.8%). High-PIV group had higher incidence (37.7% vs. 11.5%, p < 0.001) and worse MACCE-free survival (log-rank p < 0.001). Multivariate Cox confirmed high PIV as independent predictor (adjusted HR = 2.87, 95% CI: 1.55–5.32, p = 0.001). PIV AUC = 0.74 (95% CI: 0.68–0.80), outperforming SII (0.69), NLR (0.66), and PLR (0.64; DeLong's test p < 0.05 vs. NLR/PLR).
Conclusions
PIV is a robust, independent predictor of MACCE post-PCI in diabetics, with superior accuracy over other markers. It offers cost-effective risk stratification. Limitations: retrospective design; prospective validation needed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Luzhou People's Hospital, Luzhou, Sichuan, China.
- Department of Cardiology, The Fifth People's Hospital of Yibin, Yibin, Sichuan, China.
- Department of Cardiology, Fushun County Traditional Chinese Medicine, Zigong, Sichuan, China.
- Department of Cardiology, Anyue Hospital of Traditional Chinese Medicine, Anyue, Sichuan, China.
- Department of Cardiology, Longchang People's Hospital, Longchang, Sichuan, China.
- Department of Cardiology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
Zitieren
APA
Liu, Q., Tian, M., Guo, J., Chen, W., Wu, W., Yu, H., & Zhu, B. (2026). Prognostic significance of pan-immune-inflammatory value in adverse cardiovascular and cerebrovascular events post-percutaneous coronary intervention in diabetic patients with coronary heart disease. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1750706
Vancouver
Liu Q, Tian M, Guo J, Chen W, Wu W, Yu H, et al. Prognostic significance of pan-immune-inflammatory value in adverse cardiovascular and cerebrovascular events post-percutaneous coronary intervention in diabetic patients with coronary heart disease. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1750706
BibTeX
@article{Liu2026,
author = {Liu, Qinghong and Tian, Mao and Guo, Jiangjun and Chen, Wenhao and Wu, Wenting and Yu, Huadong and Zhu, Bo},
title = {Prognostic significance of pan-immune-inflammatory value in adverse cardiovascular and cerebrovascular events post-percutaneous coronary intervention in diabetic patients with coronary heart disease},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fcvm.2026.1750706}
}
EUVIMED